SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance immunotherapy in AML. ・Sellas is approaching a Phase 3 Regal survival readout, a key catalyst investors are watching closely through 2026.

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21,

SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for Galinpepimut S.

It doesn't matter how many people NASA's Space Launch System rocket eventually lands on the Moon. No matter whether it's 15 percent as estimated, 20, or even 30 percent more powerful than the Saturn V from the Apollo era, it spiritually replaces.

More than a decade after the last space shuttle took flight, NASA’s almost ready to launch a rocket once again. The Space Launch System, the most powerful rocket ever built, is designed to bring the Artemis missions to the moon, starting with Artemis I ...

The Starship rocket could take on a central role in the Artemis missions, propelling astronauts to lunar orbit and landing them on the surface.

NASA’s Artemis 2 mission, planned to launch on April 1, 2026, will test the powerful SLS rocket, Orion spacecraft, high-speed laser communications, manual rendezvous capabilities, and advanced radiation research with human “organ-on-a-chip” avatars.

NASA is restructuring how it plans to send astronauts to the Moon, giving SpaceX’s Starship a broader role in lunar transportation while the Space Launch System rocket built by Boeing faces growing questions about cost and schedule.